Neutropenic infections: A review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. D, 1998, Pages 57-64

  Marie, J P ^a   Vekhoff, A ^a   Pico, J L ^b   Guy, H ^c   Andremont, A ^b   Richet, H ^d  

^a HÔTEL DIEU   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL DU BOCAGE   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

APLASIA; ARTICLE; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION COMPLICATION; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NEUTROPENIA; RASH; SEPTICEMIA; SKIN MANIFESTATION; SUPERINFECTION;

EID: 0031798903     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_4.57     Document Type: Article

References (14)

1. EORTC International Antimicrobial Therapy Cooperative Group. (1987). Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. New England Journal of Medicine 317, 1692-8.
2. Marie, J. P., Pico, J., Lapierre, V., Maulard, C., Pappo, M., Chiche, D. et al. (1991). Traitement empirique des épisodes fébriles survenant chez les patients cancéreux présentant une neutropénie prolongée: essai comparatif ceftazidime seule, ceftazidime + amikacine et ceftazidime + vancomycine. Médecine et Maladies Infectieuses 21, 386-8.
3. Chan, C. C., Oppenheim, B. A., Anderson, H., Swindell, R. & Scarffe, J. H. C. C. (1989). Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrobial Agents and Chemotherapy 33, 87-91.
4. Gutmann, L., Kitzis, M. D., Yamabe, S. & Acar, J. F. (1986). Comparative evaluation of a new β-lactamase inhibitor, YTR 830, combined with different β-lactam antibiotics against bacteria harboring known β-lactamases. Antimicrobial Agents and Chemotherapy 29, 955-7.
5. Pico, J. L., Marie, J. P., Chiche, D., Guiguet, M., Andremont, A., Lapierre, V. et al. (1993). Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. European Journal of Medicine 2, 275-80.
6. Marie, J. P., Vekhoff, A., Pico, J. & Zittoun, R. (1995). Ceftazidime 3 grams per day for the empirical treatment of 498 febrile episodes in severely neutropenic patients. Advances in Experimental and Clinical Chemotherapy 1, 7-15.
7. Hughes, W. T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
8. Cordonnier, C., Leverger, G., Schlemmer, B., Andremont, A., Boasson, M., Herbrecht, R. et al. (1994). Stratégie antibiotique dans les épisodes fébriles au cours des neutropénies profondes (inférieures à 500 PMN) et prolongées (supérieures ou égales à 7 jours). Nouvelle Revue Française Hematologie 36, 289-91.
9. Bodey, G. P. (1993). Patients with neutropenia: old and new treatment modalities. Empirical antibiotic therapy for fever in neutropenic patients. Clinical Infectious Diseases 17, S378-84.
10. Brismar, B., Malmborg, A. S., Tunevall, G., Wretlind, B., Bergman, L., Mentzing, L. O. et al. (1993). Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrobial Agents and Chemotherapy 36, 2766-73.
11. Tan, J. S., Wishnow, R. M., Talan, D. A., Duncanson, F. P. & Norden, C. W. (1993). Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrobial Agents and Chemotherapy 37, 1580-6.
12. Cometta, A., Zinner, S., de Bock, R., Calandra, T., Gaya, H., Klastersky, J. et al. (1995). Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrobial Agents and Chemotherapy 39, 445-52.
13. Richet, H. M., Andremont, A., Tancrede, C., Pico, J. L. & Jarvis, W. R. (1991). Risk factors for candidemia in patients with acute lymphocytic leukemia. Reviews of Infectious Diseases 13, 211-5.
14. Beyer, J., Schwartz, S., Heinemann, V. & Siegert, W. (1994). Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrobial Agents and Chemotherapy 38, 911-7.